Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.06) by 37.05 percent. This is a 22.88 percent decrease over losses of $(1.18) per share from the same period last year.